经鼻高流量氧疗与无创通气治疗疑似或确诊急性心力衰竭相关急性呼吸衰竭:系统评价与Meta分析
该系统评价检索MEDLINE、Web of Science和Cochrane Library(2010年1月至2024年3月),纳入比较经鼻高流量氧疗(HFNC)与无创通气(NIV)治疗成人疑似或确诊急性心力衰竭(AHF)相关急性呼吸衰竭的随机临床试验和观察性研究。最终纳入6项研究、572例患者(HFNC 221例,NIV 351例)。随机研究中治疗失败率HFNC组20% vs NIV组13%(OR 1.7,95%CI 0.9-3.1),观察性研究中分别为34% vs 16%(OR 3.1,95%CI 0.7-13.5)。作者结论认为,与NIV相比,HFNC在AHF相关急性呼吸衰竭初始管理中未伴随更高的治疗失败风险。
要点
- 随机研究中治疗失败率HFNC组20% vs NIV组13%,OR 1.7(95%CI 0.9-3.1),未达统计学显著。
- 观察性研究中治疗失败率HFNC组34% vs NIV组16%,OR 3.1(95%CI 0.7-13.5)。
- 随机研究中插管需求HFNC组7% vs NIV组5%,OR 1.4(95%CI 0.5-3.5)。
- 随机研究中死亡率HFNC组13% vs NIV组8%,OR 1.8(95%CI 0.8-1.1)。
- 作者结论:与NIV相比,HFNC在疑似或确诊AHF相关急性呼吸衰竭初始管理中未伴随更高的治疗失败风险。
适用人群与场景
- 成人急性呼吸衰竭且由疑似或确诊急性心力衰竭(AHF)所致、需比较HFNC与NIV的患者。
研究设计与关键结果
- 系统评价与Meta分析,检索MEDLINE、Web of Science、Cochrane Library(2010年1月至2024年3月),最终纳入6项研究、572例患者(HFNC 221例,NIV 351例)。
- 随机研究中治疗失败率HFNC组20% vs NIV组13%,OR 1.7(95%CI 0.9-3.1)。
- 观察性研究中治疗失败率HFNC组34% vs NIV组16%,OR 3.1(95%CI 0.7-13.5)。
- 随机研究中气管插管需求HFNC组7% vs NIV组5%,OR 1.4(95%CI 0.5-3.5);观察性研究中HFNC组20% vs NIV组9%,OR 2.1(95%CI 0.5-9.4)。
- 随机研究中死亡率HFNC组13% vs NIV组8%,OR 1.8(95%CI 0.8-1.1);观察性研究中HFNC组14% vs NIV组9%,OR 1.4(95%CI 0.5-3.7)。
- 作者结论:与NIV相比,HFNC在疑似或确诊AHF相关急性呼吸衰竭初始管理中未伴随更高的治疗失败风险。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机临床试验及回顾性、前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于疑似或确诊AHF相关急性呼吸衰竭的初始管理,作者结论认为与NIV相比HFNC未伴随更高的治疗失败风险,可据此在床旁选择HFNC而非必须使用NIV。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The objective of this review is to compare high-flow nasal cannula (HFNC) oxygen (High flow oxygen) and noninvasive ventilation (NIV) for the management of acute respiratory failure secondary to suspected or confirmed acute heart failure (AHF). A comprehensive and relevant literature search of MEDLINE, Web of Science, and the Cochrane Library was conducted using Medical Subject Heading and Free text terms from January 2010 to March 2024. All randomized clinical trials and observational retrospective and prospective studies reporting adult patients with acute respiratory failure due to suspected or confirmed AHF and comparing HFNC to NIV were included. Primary outcome included treatment failure, as a composite outcome including early termination to the allocated treatment, need for in-hospital intubation or mortality, or the definition used in the study for treatment failure if adequate. Secondary outcomes included change in respiratory rate and dyspnea intensity after treatment initiation, patient comfort, invasive mechanical ventilation requirement, and day-30 mortality. Six of the 802 identified studies were selected for final analysis, including 572 patients (221 assigned to high flow and 351 to NIV). Treatment failure rate was 20% and 13% in the high flow oxygen and NIV groups, respectively [estimated odds ratio (OR): 1.7, 95% confidence interval (95% CI): 0.9-3.1] in randomized studies and 34% and 16% in the high flow oxygen and NIV groups, respectively (OR: 3.1, 95% CI: 0.7-13.5), in observational studies. Tracheal intubation requirement was 7% and 5% of patients in the HFNC and NIV groups, respectively (OR: 1.4, 95% CI: 0.5-3.5) in randomized studies, and 20% and 9% in the high flow oxygen and NIV group, respectively (OR: 2.1, 95% CI: 0.5-9.4) in observational studies. Mortality was 13% and 8% in the high flow oxygen and the NIV groups, respectively (OR: 1.8, 95% CI: 0.8-1.1) in randomized studies and 14% and 9% in the high flow oxygen and the NIV groups, respectively (OR: 1.4, 95% CI: 0.5-3.7) in observational studies. Compared with NIV, high flow oxygen was not associated with a higher risk of treatment failure during initial management of patients with acute respiratory failure related to suspected or confirmed AHF.
参考来源
- Marjanovic N, Couvreur R, Lamarre J, et al. High-flow nasal cannula oxygen therapy versus noninvasive ventilation in acute respiratory failure related to suspected or confirmed acute heart failure: a systematic review with meta-analysis. Eur J Emerg Med. 2024. PMID: 39166964. doi:10.1097/MEJ.0000000000001171
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。